Navigation Links
Secca(R) Therapy - An Effective and Minimally Invasive Option for Treating Bowel Incontinence - Launched in the US
Date:8/31/2009

GREENWICH, Conn., Aug. 31 /PRNewswire/ -- Mederi Therapeutics Inc. announces the US release of the Secca system for treatment of bowel incontinence. Secca Therapy is a minimally invasive procedure for a debilitating and embarrassing condition that affects tens of millions of Americans, both young and old. Secca therapy delivers radiofrequency (RF) energy to the muscles of the anal canal - tightening the muscles, producing better bowel control and reducing the symptoms of incontinence.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090831/NY67762 )

"This innovative treatment bridges the gap between often unsuccessful conservative measures, such as diet modification and biofeedback, and expensive and disfiguring surgical treatment," said Mederi CEO, Will Rutan. "The effect of bowel incontinence on quality of life is devastating, so the overwhelmingly positive response to the release of the Secca system is not surprising."

Secca therapy is an outpatient procedure that takes approximately 45 minutes and is performed in an endoscopy suite or ambulatory surgery unit, with the patient under general anesthesia or conscious sedation. Patients go home approximately one to two hours after the procedure and, typically, resume normal activities within several days. In clinical trials as many as 8 out of 10 patients had a positive clinical response to Secca therapy and showed significant improvement in quality of life scores. Further, recent clinical studies have shown symptom relief lasting as long as five years.

The dominant cause of bowel incontinence is damage to the pelvic floor during normal childbirth, thus, a significant majority of sufferers are women, seventy percent of whom are under the age of 65. In the elderly, bowel incontinence is cited as the second leading reason to institutionalize loved ones and over 45 percent of residents in nursing homes suffer from this condition.

Due to the embarrassment associated with bowel incontinence, studies report that fewer than one in five people with this condition have discussed it with their doctors. These factors indicate that bowel incontinence is both a well-guarded and under-reported illness.

Additional information is available at www.mederitherapeutics.com or www.secca-therapy.com.

ABOUT MEDERI

Mederi Therapeutics manufactures and markets innovative medical devices that deliver radiofrequency energy to treat disease states affecting the human digestive system. All Mederi therapies are outpatient, minimally invasive, and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.

    Contact: Sheila Doyle
    Manager of Communications and Marketing
    203 930 9980


'/>"/>
SOURCE Mederi Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Vision restoration therapy shown to improve brain activity in brain injured patients
2. HIV therapy in pregnancy-data support WHO recommendations
3. Family-based treatment more effective than supportive psychotherapy in treating bulimia
4. Trial to Test Gene Therapy for Angina in Women
5. One of the Largest Post-WHI Physician Surveys Shows More Education is Needed: Patient Misinformation About Hormone Therapy Remains High
6. Aromatherapy Gift Line Sheds Humorous Light on Modern Therapy
7. Chemotherapy may be culprit for fatigue in breast cancer survivors
8. Atlanta Falcons Physical Therapy Centers Set to Launch This Fall
9. New Drug No Substitute for Standard Blood-Clot Therapy
10. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
11. Nucletron Announces Management Buy-Out to More Effectively Meet the Demands of Its Customers and the Radiation Therapy Community
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , ... January 18, 2017 , ... ... announce that their Vice President of Franchise Development, Paula Turner Pizarro, was recently ... business program, which features the insights of top business leaders from across the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... solutions for drugs, biologics and consumer health products, today announced that Mr. Michael ... the upcoming WCBP Conference, to be held at the Mayflower Hotel, Washington DC, ...
(Date:1/18/2017)... ... ... Floundering on New Year’s resolutions? Need an excuse to get back on ... U.S. Apple Association agrees and recommends starting each day with apples, a habit ... disease. , The U.S. Apple Association – which represents apple growers and producers nationwide ...
(Date:1/17/2017)... ... ... For breast cancer clinicians and researchers who were unable to attend the ... review and analysis of its highlights, a novel half-day, complimentary meeting—the 14th Annual Best ... February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, FACP, FASCO from ...
(Date:1/17/2017)... ... January 17, 2017 , ... Etymotic Research will demonstrate ... Music Merchants (NAMM) winter trade show, Booth #2876, at the Anaheim Convention Center ... been the gold standard for high-definition, in-ear earphones. This classic earphone has been ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... 2017  Dermata Therapeutics, LLC, a biotechnology company ... variety of dermatological diseases, announces dosing the first ... Phase 2 acne rosacea study. DMT210 is a ... cytokines in the skin responsible for the inflammation ... This clinical trial, DMT210-003, is a 12-week, ...
(Date:1/18/2017)... enero de 2017  Hoy, en el Foro Económico ... iniciativa global para avanzar el acceso a la prevención ... de renta baja y baja-media (LICs y LMICs). ... crisis, particularmente en países de renta baja y media, ... las muertes relacionadas con NCD. El objetivo de Access ...
(Date:1/18/2017)... -- With an annual growth ranging from 6% to 10%, South East Asia,s ... Expo, March 22-24, 2017) serves the industry by fostering the regional discourse - ... Investment Forum ASEAN -- India ... content Enhanced business matchmaking program Roadshows ... ...
Breaking Medicine Technology: